Synthetic Inhibitors of Nucleoside Monophosphate-Kinases
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 25 September 2024 | Viewed by 147
Special Issue Editors
Interests: adenylate kinase; enzymatic inhibitors; antibiotic resistance; natural products
Interests: antibiotics discovery; anticancerous drugs discovery; medicinal chemistry; organic synthesis
Special Issues, Collections and Topics in MDPI journals
Interests: computational chemistry; drug discovery; medicinal chemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The scope of the new Special issue on the inhibitors of nucleoside monophosphate-kinases (NMP kinases) (EC 2.7.4.4) is motivated by the key role of NMP kinases in metabolism, cell division and other essential cellular functions. These kinases are essential enzymes that catalyse the reversible phosphorylation of nucleoside monophospates in nucleoside diphospates. ATP is the most efficient phosphate donor. The NMP kinases involved in purine metabolism are the adenylate kinase (AMP kinase) and guanilate kinase (GMP kinase); those involved in pyrimidinic metabolism are tymidilate kinase (TMP kinase), urydilate kinase (UMP kinase), and cytidilate kinase (CMP kinase); and for eucaryotes, there is the bi-functional enzyme UMP/CMP kinase. Biochemical and crystallographic studies characterize the catalytic and structural properties of many NMP kinases. The structural and catalytic differences between bacterial NMP kinases and their eukaryotic counterparts allows advancing studies on the inhibitors of these enzymes. Mutagenesis studies greatly advance the understanding of the regulation of NMP kinases by different ligands. Principally, we are interested in the connection of human adenylate kinases and their mutants with pathological conditions. There are nine isoenzymes and several subforms of adenylate kinases described in eukaryotes that differ from their bacterial counterparts. The adenylate kinases and other NMP kinases can be viable targets for new synthetic or natural compounds.
We welcome research articles and reviews that advance the knowledge about the field of inhibitors of NMP kinases.
Dr. Mihaela Ileana Ionescu
Prof. Dr. Ovidiu Oniga
Dr. Cristina Nastasă
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nucleoside monophosphate-kinases
- adenylate kinase
- urydilate kinase
- tymidilate kinase
- guanilate kinase
- cytidilate kinase
- natural inhibitors
- enzymatic activity
- drug design
- structural studies
